Search for "piperidine" in Full Text gives 273 result(s) in Beilstein Journal of Organic Chemistry. Showing first 200.
Beilstein J. Org. Chem. 2021, 17, 2488–2495, doi:10.3762/bjoc.17.165
Graphical Abstract
Scheme 1: 3d-Transition-metal-catalyzed C–H functionalization to access functionalized ferrocenes.
Scheme 2: Scope of ferrocenes with morpholine.
Scheme 3: Scope of various amines with 1a.
Scheme 4: Synthetic applications.
Scheme 5: Mechanistic experiments.
Beilstein J. Org. Chem. 2021, 17, 2348–2376, doi:10.3762/bjoc.17.153
Graphical Abstract
Scheme 1: Schematic representation of Hg(II)-mediated addition to an unsaturated bond.
Scheme 2: First report of Hg(II)-mediated synthesis of 2,5-dioxane derivatives from allyl alcohol.
Scheme 3: Stepwise synthesis of 2,6-distubstituted dioxane derivatives.
Scheme 4: Cyclization of carbohydrate alkene precursor.
Scheme 5: Hg(II)-mediated synthesis of C-glucopyranosyl derivatives.
Scheme 6: Synthesis of C-glycosyl amino acid derivative using Hg(TFA)2.
Scheme 7: Hg(OAc)2-mediated synthesis of α-ᴅ-ribose derivative.
Scheme 8: Synthesis of β-ᴅ-arabinose derivative 18.
Scheme 9: Hg(OAc)2-mediated synthesis of tetrahydrofuran derivatives.
Scheme 10: Synthesis of Hg(TFA)2-mediated bicyclic nucleoside derivative.
Scheme 11: Synthesis of pyrrolidine and piperidine derivatives.
Scheme 12: HgCl2-mediated synthesis of diastereomeric pyrrolidine derivatives.
Scheme 13: HgCl2-mediated cyclization of alkenyl α-aminophosphonates.
Scheme 14: Cyclization of 4-cycloocten-1-ol with Hg(OAc)2 forming fused bicyclic products.
Scheme 15: trans-Amino alcohol formation through Hg(II)-salt-mediated cyclization.
Scheme 16: Hg(OAc)2-mediated 2-aza- or 2-oxa-bicyclic ring formations.
Scheme 17: Hg(II)-salt-induced cyclic peroxide formation.
Scheme 18: Hg(OAc)2-mediated formation of 1,2,4-trioxanes.
Scheme 19: Endocyclic enol ether derivative formation through Hg(II) salts.
Scheme 20: Synthesis of optically active cyclic alanine derivatives.
Scheme 21: Hg(II)-salt-mediated formation of tetrahydropyrimidin-4(1H)-one derivatives.
Scheme 22: Cyclization of ether derivatives to form stereoselective oxazolidine derivatives.
Scheme 23: Cyclization of amide derivatives induced by Hg(OAc)2.
Scheme 24: Hg(OAc)2/Hg(TFA)2-promoted cyclization of salicylamide-derived amidal auxiliary derivatives.
Scheme 25: Hg(II)-salt-mediated cyclization to form dihydrobenzopyrans.
Scheme 26: HgCl2-induced cyclization of acetylenic silyl enol ether derivatives.
Scheme 27: Synthesis of exocyclic and endocyclic enol ether derivatives.
Scheme 28: Cyclization of trans-acetylenic alcohol by treatment with HgCl2.
Scheme 29: Synthesis of benzofuran derivatives in presence of HgCl2.
Scheme 30: a) Hg(II)-salt-mediated cyclization of 4-hydroxy-2-alkyn-1-ones to furan derivatives and b) its mec...
Scheme 31: Cyclization of arylacetylenes to synthesize carbocyclic and heterocyclic derivatives.
Scheme 32: Hg(II)-salt-promoted cyclization–rearrangement to form heterocyclic compounds.
Scheme 33: a) HgCl2-mediated cyclization reaction of tethered alkyne dithioacetals; and b) proposed mechanism.
Scheme 34: Cyclization of aryl allenic ethers on treatment with Hg(OTf)2.
Scheme 35: Hg(TFA)2-mediated cyclization of allene.
Scheme 36: Hg(II)-catalyzed intramolecular trans-etherification reaction of 2-hydroxy-1-(γ-methoxyallyl)tetrah...
Scheme 37: a) Cyclization of alkene derivatives by catalytic Hg(OTf)2 salts and b) mechanism of cyclization.
Scheme 38: a) Synthesis of 1,4-dihydroquinoline derivatives by Hg(OTf)2 and b) plausible mechanism of formatio...
Scheme 39: Synthesis of Hg(II)-salt-catalyzed heteroaromatic derivatives.
Scheme 40: Hg(II)-salt-catalyzed synthesis of dihydropyranone derivatives.
Scheme 41: Hg(II)-salt-catalyzed cyclization of alkynoic acids.
Scheme 42: Hg(II)-salt-mediated cyclization of alkyne carboxylic acids and alcohol to furan, pyran, and spiroc...
Scheme 43: Hg(II)-salt-mediated cyclization of 1,4-dihydroxy-5-alkyne derivatives.
Scheme 44: Six-membered morpholine derivative formation by catalytic Hg(II)-salt-induced cyclization.
Scheme 45: Hg(OTf)2-catalyzed hydroxylative carbocyclization of 1,6-enyne.
Scheme 46: a) Hg(OTf)2-catalyzed hydroxylative carbocyclization of 1,6-enyne. b) Proposed mechanism.
Scheme 47: a) Synthesis of carbocyclic derivatives using a catalytic amount of Hg(II) salt. b) Proposed mechan...
Scheme 48: Cyclization of 1-alkyn-5-ones to 2-methylfuran derivatives.
Scheme 49: Hg(NO3)2-catalyzed synthesis of 2-methylenepiperidine.
Scheme 50: a) Preparation of indole derivatives through cycloisomerization of 2-ethynylaniline and b) its mech...
Scheme 51: a) Hg(OTf)2-catalyzed synthesis of 3-indolinones and 3-coumaranones and b) simplified mechanism.
Scheme 52: a) Hg(OTf)2-catalyzed one pot cyclization of nitroalkyne and b) its plausible mechanism.
Scheme 53: Synthesis of tricyclic heterocyclic scaffolds.
Scheme 54: HgCl2-mediated cyclization of 2-alkynylphenyl alkyl sulfoxide.
Scheme 55: a) Hg(OTf)2-catalyzed cyclization of allenes and alkynes. b) Proposed mechanism of cyclization.
Scheme 56: Stereoselective synthesis of tetrahydropyran derivatives.
Scheme 57: a) Hg(ClO4)2-catalyzed cyclization of α-allenol derivatives. b) Simplified mechanism.
Scheme 58: Hg(TFA)2-promoted cyclization of a γ-hydroxy alkene derivative.
Scheme 59: Synthesis Hg(II)-salt-mediated cyclization of allyl alcohol for the construction of ventiloquinone ...
Scheme 60: Hg(OAc)2-mediated cyclization as a key step for the synthesis of hongconin.
Scheme 61: Examples of Hg(II)-salt-mediated cyclized ring formation in the syntheses of (±)-fastigilin C and (...
Scheme 62: Formal synthesis of (±)-thallusin.
Scheme 63: Total synthesis of hippuristanol and its analog.
Scheme 64: Total synthesis of solanoeclepin A.
Scheme 65: a) Synthesis of Hg(OTf)2-catalyzed azaspiro structure for the formation of natural products. b) Pro...
Beilstein J. Org. Chem. 2021, 17, 1981–2025, doi:10.3762/bjoc.17.129
Graphical Abstract
Figure 1: Overview of the methods available for the synthesis of polysaccharides. For each method, advantages...
Figure 2: Overview of the classes of polysaccharides discussed in this review. Each section deals with polysa...
Scheme 1: Enzymatic and chemical polymerization approaches provide cellulose oligomers with a non-uniform dis...
Scheme 2: AGA of a collection of cellulose analogues obtained using BBs 6–9. Specifically placed modification...
Figure 3: Chemical structure of the different branches G, X, L, F commonly found in XGs. Names are given foll...
Scheme 3: AGA of XG analogues with defined side chains. The AGA cycle includes coupling (TMSOTf), Fmoc deprot...
Figure 4: Synthetic strategies and issues associated to the formation of the β(1–3) linkage.
Scheme 4: Convergent synthesis of β(1–3)-glucans using a regioselective glycosylation strategy.
Scheme 5: DMF-mediated 1,2-cis glycosylation. A) General mechanism and B) examples of α-glucans prepared usin...
Scheme 6: Synergistic glycosylation strategy employing a nucleophilic modulation strategy (TMSI and Ph3PO) in...
Scheme 7: Different approaches to produce xylans. A) Polymerization techniques including ROP, and B) enzymati...
Scheme 8: A) Synthesis of arabinofuranosyl-decorated xylan oligosaccharides using AGA. Representative compoun...
Scheme 9: Chemoenzymatic synthesis of COS utilizing a lysozyme-catalyzed transglycosylation reaction followed...
Scheme 10: Synthesis of COS using an orthogonal glycosylation strategy based on the use of two different LGs.
Scheme 11: Orthogonal N-PGs permitted the synthesis of COS with different PA.
Scheme 12: AGA of well-defined COS with different PA using two orthogonally protected BBs. The AGA cycle inclu...
Scheme 13: A) AGA of β(1–6)-N-acetylglucosamine hexasaccharide and dodecasaccharide. AGA includes cycles of co...
Figure 5: ‘Double-faced’ chemistry exemplified for ᴅ-Man and ʟ-Rha. Constructing β-Man linkages is considerab...
Figure 6: Implementation of a capping step after each glycosylation cycle for the AGA of a 50mer oligomannosi...
Scheme 14: AGA enabled the synthesis of a linear α(1–6)-mannoside 100mer 93 within 188 h and with an average s...
Scheme 15: The 151mer branched polymannoside was synthesized by a [30 + 30 + 30 + 30 + 31] fragment coupling. ...
Figure 7: PG stereocontrol strategy to obtain β-mannosides. A) The mechanism of the β-mannosylation reaction ...
Scheme 16: A) Mechanism of 1,2-cis stereoselective glycosylation using ManA donors. Once the ManA donor is act...
Figure 8: A) The preferred 4H3 conformation of the gulosyl oxocarbenium ion favors the attack of the alcohol ...
Scheme 17: AGA of type I rhamnans up to 16mer using disaccharide BB 115 and CNPiv PG. The AGA cycle includes c...
Figure 9: Key BBs for the synthesis of the O-antigen of Bacteroides vulgatus up to a 128mer (A) and the CPS o...
Figure 10: Examples of type I and type II galactans synthesized to date.
Figure 11: A) The DTBS PG stabilizes the 3H4 conformation of the Gal oxocarbenium ion favoring the attack of t...
Figure 12: Homogalacturonan oligosaccharides synthesized to date. Access to different patterns of methyl-ester...
Figure 13: GlfT2 from Mycobacterium tuberculosis catalyzes the sequential addition of UPD-Galf donor to a grow...
Figure 14: The poor reactivity of acceptor 137 hindered a stepwise synthesis of the linear galactan backbone a...
Scheme 18: AGA of a linear β(1–5) and β(1–6)-linked galactan 20mer. The AGA cycle includes coupling (NIS/TfOH)...
Figure 15: The 92mer arabinogalactan was synthesized using a [31 + 31 + 30] fragment coupling between a 31mer ...
Scheme 19: Synthesis of the branched arabinofuranose fragment using a six component one-pot synthesis. i) TTBP...
Figure 16: A) Chemical structure and SNFG of the representative disaccharide units forming the GAG backbones, ...
Figure 17: Synthetic challenges associated to the H/HS synthesis.
Scheme 20: Degradation of natural heparin and heparosan generated valuable disaccharides 150 and 151 that can ...
Scheme 21: A) The one-step conversion of cyanohydrin 156 to ʟ-iduronamide 157 represent the key step for the s...
Scheme 22: A) Chemoenzymatic synthesis of heparin structures, using different types of UDP activated natural a...
Scheme 23: Synthesis of the longest synthetic CS chain 181 (24mer) using donor 179 and acceptor 180 in an iter...
Scheme 24: AGA of a collection of HA with different lengths. The AGA cycle includes coupling (TfOH) and Lev de...
Beilstein J. Org. Chem. 2021, 17, 1952–1980, doi:10.3762/bjoc.17.128
Graphical Abstract
Figure 1: Coumarin-derived commercially available drugs.
Figure 2: Inhibition of acetylcholinesterase by coumarin derivatives.
Scheme 1: Michael addition of 4-hydroxycoumarins 1 to α,β‐unsaturated enones 2.
Scheme 2: Organocatalytic conjugate addition of 4-hydroxycoumarin 1 to α,β-unsaturated aldehydes 2 followed b...
Scheme 3: Synthesis of 3,4-dihydrocoumarin derivatives 10 through decarboxylative and dearomatizative cascade...
Scheme 4: Total synthesis of (+)-smyrindiol (17).
Scheme 5: Michael addition of 4-hydroxycoumarin (1) to enones 2 through a bifunctional modified binaphthyl or...
Scheme 6: Michael addition of ketones 20 to 3-aroylcoumarins 19 using a cinchona alkaloid-derived primary ami...
Scheme 7: Enantioselective reaction of cyclopent-2-enone-derived MBH alcohols 24 with 4-hydroxycoumarins 1.
Scheme 8: Sequential Michael addition/hydroalkoxylation one-pot approach to annulated coumarins 28 and 30.
Scheme 9: Michael addition of 4-hydroxycoumarins 1 to enones 2 using a binaphthyl diamine catalyst 31.
Scheme 10: Asymmetric Michael addition of 4-hydroxycoumarin 1 with α,β-unsaturated ketones 2 catalyzed by a ch...
Scheme 11: Catalytic asymmetric β-C–H functionalization of ketones via enamine oxidation.
Scheme 12: Enantioselective synthesis of polycyclic coumarin derivatives 37 catalyzed by an primary amine-imin...
Scheme 13: Allylic alkylation reaction between 3-cyano-4-methylcoumarins 39 and MBH carbonates 40.
Scheme 14: Enantioselective synthesis of cyclopropa[c]coumarins 45.
Scheme 15: NHC-catalyzed lactonization of 2-bromoenals 46 with 4-hydroxycoumarin (1).
Scheme 16: NHC-catalyzed enantioselective synthesis of dihydrocoumarins 51.
Scheme 17: Domino reaction of enals 2 with hydroxylated malonate 53 catalyzed by NHC 55.
Scheme 18: Oxidative [4 + 2] cycloaddition of enals 57 to coumarins 56 catalyzed by NHC 59.
Scheme 19: Asymmetric [3 + 2] cycloaddition of coumarins 43 to azomethine ylides 60 organocatalyzed by quinidi...
Scheme 20: Synthesis of α-benzylaminocoumarins 64 through Mannich reaction between 4-hydroxycoumarins (1) and ...
Scheme 21: Asymmetric addition of malonic acid half-thioesters 67 to coumarins 66 using the sulphonamide organ...
Scheme 22: Enantioselective 1,4-addition of azadienes 71 to 3-homoacyl coumarins 70.
Scheme 23: Michael addition/intramolecular cyclization of 3-acylcoumarins 43 to 3-halooxindoles 74.
Scheme 24: Enantioselective synthesis of 3,4-dihydrocoumarins 78 catalyzed by squaramide 73.
Scheme 25: Organocatalyzed [4 + 2] cycloaddition between 2,4-dienals 79 and 3-coumarincarboxylates 43.
Scheme 26: Enantioselective one-pot Michael addition/intramolecular cyclization for the synthesis of spiro[dih...
Scheme 27: Michael/hemiketalization addition enantioselective of hydroxycoumarins (1) to: (a) enones 2 and (b)...
Scheme 28: Synthesis of 2,3-dihydrofurocoumarins 89 through Michael addition of 4-hydroxycoumarins 1 to β-nitr...
Scheme 29: Synthesis of pyrano[3,2-c]chromene derivatives 93 via domino reaction between 4-hydroxycoumarins (1...
Scheme 30: Conjugated addition of 4-hydroxycoumarins 1 to nitroolefins 95.
Scheme 31: Michael addition of 4-hydroxycoumarin 1 to α,β-unsaturated ketones 2 promoted by primary amine thio...
Scheme 32: Enantioselective synthesis of functionalized pyranocoumarins 99.
Scheme 33: 3-Homoacylcoumarin 70 as 1,3-dipole for enantioselective concerted [3 + 2] cycloaddition.
Scheme 34: Synthesis of warfarin derivatives 107 through addition of 4-hydroxycoumarins 1 to β,γ-unsaturated α...
Scheme 35: Asymmetric multicatalytic reaction sequence of 2-hydroxycinnamaldehydes 109 with 4-hydroxycoumarins ...
Scheme 36: Mannich asymmetric addition of cyanocoumarins 39 to isatin imines 112 catalyzed by the amide-phosph...
Scheme 37: Enantioselective total synthesis of (+)-scuteflorin A (119).
Beilstein J. Org. Chem. 2021, 17, 1752–1813, doi:10.3762/bjoc.17.123
Graphical Abstract
Scheme 1: Fluorination with N-F amine 1-1.
Scheme 2: Preparation of N-F amine 1-1.
Scheme 3: Reactions of N-F amine 1-1.
Scheme 4: Synthesis of N-F perfluoroimides 2-1 and 2-2.
Scheme 5: Synthesis of 1-fluoro-2-pyridone (3-1).
Scheme 6: Fluorination with 1-fluoro-2-pyridone (3-1).
Figure 1: Synthesis of N-F sulfonamides 4-1a–g.
Scheme 7: Fluorination with N-F reagent 4-1b,c,f.
Scheme 8: Fluorination of alkenyllithiums with N-F 4-1h.
Scheme 9: Synthesis of N-fluoropyridinium triflate (5-4a).
Scheme 10: Synthetic methods for N-F-pyridinium salts.
Figure 2: Synthesis of various N-fluoropyridinium salts. Note: athis yield was the one by the improved method...
Scheme 11: Fluorination power order of N-fluoropyridinium salts.
Scheme 12: Fluorinations with N-F salts 5-4.
Scheme 13: Fluorination of Corey lactone 5-7 with N-F-bis(methoxymethyl) salt 5-4l.
Scheme 14: Fluorination with NFPy.
Scheme 15: Synthesis of the N-F reagent, N-fluoroquinuclidinium fluoride (6-1).
Scheme 16: Fluorinations achieved with N-F fluoride 6-1.
Scheme 17: Synthesis of N-F imides 7-1a–g.
Scheme 18: Fluorination with (CF3SO2)2NF, 7-1a.
Scheme 19: Fluorination reactions of various substrates with 7-1a.
Scheme 20: Synthesis of N-F triflate 8-1.
Scheme 21: Synthesis of chiral N-fluoro sultams 9-1 and 9-2.
Scheme 22: Fluorination with chiral N-fluoro sultams 9-1 and 9-2.
Scheme 23: Synthesis of saccharin-derived N-fluorosultam 10-2.
Scheme 24: Fluorination with N-fluorosultam 10-2.
Scheme 25: Synthesis of N-F reagent 11-2.
Scheme 26: Fluorination with N-F reagent 11-2.
Scheme 27: Synthesis and reaction of N-fluorolactams 12-1.
Scheme 28: Synthesis of NFOBS 13-2.
Scheme 29: Fluorination with NFOBS 13-2.
Scheme 30: Synthesis of NFSI (14-2).
Scheme 31: Fluorination with NFSI 14-2.
Scheme 32: Synthesis of N-fluorosaccharin (15-1) and N-fluorophthalimide (15-2).
Scheme 33: Synthesis of N-F salts 16-3.
Scheme 34: Fluorination with N-F salts 16-3.
Figure 3: Monofluorination with Selectfluor (16-3a).
Figure 4: Difluorination with Selectfluor (16-3a).
Scheme 35: Transfer fluorination of Selectfluor (16-3a).
Scheme 36: Fluorination of substrates with Selectfluor (16-3a).
Scheme 37: Synthesis of chiral N-fluoro-sultam 17-2.
Scheme 38: Asymmetric fluorination with chiral 17-2.
Figure 5: Synthesis of Zwitterionic N-fluoropyridinium salts 18-2a–h.
Scheme 39: Fluorinating power order of zwitterionic N-fluoropyridinium salts.
Scheme 40: Fluorination with zwitterionic 18-2.
Scheme 41: Activation of salt 18-2h with TfOH.
Scheme 42: Synthesis of NFTh, 19-2.
Scheme 43: Fluorination with NFTh, 19-2.
Scheme 44: Synthesis of 3-fluorobenzo-1,2,3-oxathiazin-4-one 2,2-dioxide (20-2).
Scheme 45: Fluorination with 20-2.
Scheme 46: Synthesis of N-F amide 21-3.
Scheme 47: Fluorination with N-F amide 21-2.
Scheme 48: Synthesis of N,N’-difluorodiazoniabicyclo[2.2.2]octane salts 22-1.
Scheme 49: One-pot synthesis of N,N’-difluoro-1,4-diazoniabicyclo[2.2.2]octane bistetrafluoroborate salt (22-1d...
Figure 6: Fluorination of anisole with 22-1a, d, e.
Scheme 50: Fluorination with N,N’-diF bisBF4 22-1d.
Scheme 51: Synthesis of bis-N-F reagents 23-1–5.
Scheme 52: Fluorination with 23-2, 4, 5.
Figure 7: Synthesis of N,N’-difluorobipyridinium salts 24-2.
Figure 8: Controlled fluorination of N,N’-diF 24-2.
Scheme 53: Fluorinating power of N,N’-diF salts 24-2 and N-F salt 5-4a.
Scheme 54: Fluorination reactions with SynfluorTM (24-2b).
Scheme 55: Additional fluorination reactions with SynfluorTM (24-2b).
Scheme 56: Synthesis of N-F 25-1.
Scheme 57: Fluorination of polycyclic aromatics with 25-1.
Scheme 58: Synthesis of 26-1 and dimethyl analog 26-2.
Scheme 59: Fluorination with reagents 26-1, 26-2, 1-1, and 26-3.
Scheme 60: Synthesis of N-F reagent 27-2.
Scheme 61: Synthesis of chiral N-F reagents 27-6.
Scheme 62: Synthesis of chiral N-F 27-7–9.
Scheme 63: Asymmetric fluorination with 27-6.
Scheme 64: Synthesis of chiral N-F reagents 28-3.
Scheme 65: Asymmetric fluorination with 28-3.
Scheme 66: Synthesis of chiral N-F reagents 28-7.
Figure 9: Asymmetric fluorination with 28-7.
Scheme 67: In situ formation of N-fluorinated cinchona alkaloids with SelectfluorTM.
Scheme 68: Asymmetric fluorination with N-F alkaloids formed in situ.
Scheme 69: Synthesis of N-fluorocinchona alkaloids with Selectfluor.
Scheme 70: Asymmetric fluorination with 30-1–4.
Scheme 71: Transfer fluorination from various N-F reagents.
Figure 10: Asymmetric fluorination of silyl enol ethers.
Scheme 72: Synthesis of N-fluoro salt 32-2.
Scheme 73: Reactivity of N-fluorotriazinium salt 32-2.
Scheme 74: Synthesis of bulky N-fluorobenzenesulfonimide NFBSI 33-3.
Scheme 75: Comparison of NFSI and NFBSI.
Scheme 76: Synthesis of p-substituted N-fluorobenzenesulfonimides 34-3.
Figure 11: Asymmetric fluorination with 34-3 and a chiral catalyst 34-4.
Scheme 77: 1,4-Fluoroamination with Selecfluor and a chiral catalyst.
Figure 12: Asymmetric fluoroamination with 35-5a, b.
Scheme 78: Synthesis of Selectfluor analogs 35-5a, b.
Scheme 79: Synthesis of chiral dicationic DABCO-based N-F reagents 36-5.
Scheme 80: Asymmetric fluorocyclization with chiral 36-5b.
Scheme 81: Synthesis of chiral 37-2a,b.
Scheme 82: Asymmetric fluorination with chiral 37-2a,b.
Scheme 83: Asymmetric fluorination with chiral 37-2b.
Scheme 84: Reaction of indene with chiral 37-2a,b.
Scheme 85: Synthesis of Me-NFSI, 38-2.
Scheme 86: Fluorination of active methine compounds with Me-NFSI.
Scheme 87: Fluorination of malonates with Me-NFSI.
Scheme 88: Fluorination of keto esters with Me-NFSI.
Scheme 89: Synthesis of N-F 39-3 derived from the ethylene-bridged Tröger’s base.
Scheme 90: Fluorine transfer from N-F 39-3.
Scheme 91: Fluorination with N-F 39-3.
Scheme 92: Synthesis of SelectfluorCN.
Scheme 93: Bistrifluoromethoxylation of alkenes using SelectfluorCN.
Figure 13: Synthesis of NFAS 41-2.
Scheme 94: Radical fluorination with different N-F reagents.
Scheme 95: Radical fluorination of alkenes with NFAS 41-2.
Scheme 96: Radical fluorination of alkenes with NFAS 41-2f.
Scheme 97: Decarboxylative fluorination with NFAS 41-2a,f.
Scheme 98: Fluorine plus detachment (FPD).
Figure 14: FPD values of representative N-F reagents in CH2Cl2 and CH3CN (in parentheses). Adapted with permis...
Scheme 99: N-F homolytic bond dissociation energy (BDE).
Figure 15: BDE values of representative N-F reagents in CH3CN. Adapted with permission from ref. [127]. Copyright 2...
Figure 16: Quantitative reactivity scale for popular N-F reagents. Adapted with permission from ref. [138], publish...
Scheme 100: SET and SN2 mechanisms.
Scheme 101: Radical clock reactions.
Scheme 102: Reaction of potassium enolate of citronellic ester with N-F reagents, 10-1, NFSI, and 8-1.
Scheme 103: Reaction of compound IV with Selectfluor (OTf) and NFSI.
Scheme 104: Reaction of TEMPO with Selecfluor.
Beilstein J. Org. Chem. 2021, 17, 1600–1628, doi:10.3762/bjoc.17.114
Graphical Abstract
Figure 1: Some significant triazole derivatives [8,23-27].
Scheme 1: A general comparison between synthetic routes for disubstituted 1,2,3-triazole derivatives and full...
Scheme 2: Synthesis of formyltriazoles 3 from the treatment of α-bromoacroleins 1 with azides 2.
Scheme 3: A probable mechanism for the synthesis of formyltriazoles 5 from the treatment of α-bromoacroleins 1...
Scheme 4: Synthesis of 1,4,5-trisubstituted 1,2,3-triazoles 8 from the reaction of aryl azides 7 with enamino...
Scheme 5: Proposed mechanism for the synthesis of 1,4,5-trisubstituted 1,2,3-triazoles from the reaction of a...
Scheme 6: Synthesis of 1,4,5-trisubstituted 1,2,3-triazoles 11 from the reaction of primary amines 10 with 1,...
Scheme 7: The proposed mechanism for the synthesis of 1,4,5-trisubstituted 1,2,3-triazoles 11 from the reacti...
Scheme 8: Synthesis of fully decorated 1,2,3-triazoles 19 containing a sulfur-based side chain.
Scheme 9: Mechanism for the formation of fully decorated 1,2,3-triazoles 19 containing a sulfur-based side ch...
Scheme 10: Synthesis of fully decorated 1,2,3-triazole compounds 25 through the regioselective addition and cy...
Scheme 11: A reasonable mechanism for the synthesis of fully decorated 1,2,3-triazole compounds 25 through the...
Scheme 12: Synthesis of 1,4,5-trisubstituted glycosyl-containing 1,2,3-triazole derivatives 30 from the reacti...
Scheme 13: Synthesis of 1,4,5-trisubstituted 1,2,3-triazoles 34 via intramolecular cyclization reaction of ket...
Scheme 14: Synthesis of fully decorated 1,2,3-triazoles 38 from the reaction of aldehydes 35, amines 36, and α...
Scheme 15: A reasonable mechanism for the synthesis of fully decorated 1,2,3-triazoles 38 from the reaction of...
Scheme 16: Synthesis of functionally rich double C- and N-vinylated 1,2,3-triazoles 45 and 47.
Scheme 17: Synthesis of disubstituted 4-chloro-, 4-bromo-, and 4-iodo-1,2,3-triazoles 50.
Scheme 18: a) A general route for SPAAC in polymer chemistry and b) synthesis of a novel pH-sensitive polymeri...
Scheme 19: Synthesis of 5-allenyl-1,2,3-triazoles 60 by the treatment of alkynes 57, azides 58, and propargyli...
Scheme 20: A reasonable mechanism for the synthesis of 5-allenyl-1,2,3-triazoles 60 by the treatment of alkyne...
Scheme 21: Synthesis of 5‐alkynyl-1,2,3-triazoles 69.
Scheme 22: A reasonable mechanism for the synthesis of 5‐alkynyl-1,2,3-triazoles 69.
Scheme 23: Synthesis of sulfur-cycle-fused 1,2,3-triazoles 75 and 77.
Scheme 24: A reasonable mechanism for the synthesis of sulfur-cycle-fused 1,2,3‐triazoles 75 and 77.
Scheme 25: Synthesis of 5-selanyltriazoles 85 from the reaction of ethynylstibanes 82, organic azides 83, and ...
Scheme 26: A mechanism for the synthesis of 5-selanyltriazoles 85 from the reaction of ethynylstibanes 82, org...
Scheme 27: Synthesis of trisubstituted triazoles containing an Sb substituent at position C5 in 93 and 5-unsub...
Scheme 28: Synthesis of asymmetric triazole disulfides 98 from disulfide-containing tert-butyltosyl disulfide 97...
Scheme 29: A mechanism for the synthesis of asymmetric triazole disulfides 98 from disulfide-containing tert-bu...
Scheme 30: Synthesis of triazole-fused sultams 104.
Scheme 31: Synthesis of 1,2,3-triazole-fused tricyclic heterocycles 106.
Scheme 32: A reasonable mechanism for the synthesis of 1,2,3-triazole-fused tricyclic heterocycles 106.
Scheme 33: Synthesis of 5-aryl-substituted 1,2,3-triazole derivatives 112.
Scheme 34: A reasonable mechanism for the synthesis of 5-aryl-substituted 1,2,3-triazole derivatives 112.
Scheme 35: Synthesis of 1,4,5-trisubstituted 1,2,3-triazole-5-carboxamides 119.
Scheme 36: A probable mechanism for the synthesis of 1,4,5-trisubstituted 1,2,3-triazole-5-carboxamides 119.
Scheme 37: Synthesis of fully decorated triazoles 125 via the Pd/C-catalyzed arylation of disubstituted triazo...
Scheme 38: Synthesis of triazolo[1,5-a]indolones 131.
Scheme 39: Synthesis of unsymmetrically substituted triazole-fused enediyne systems 135 and 5-aryl-4-ethynyltr...
Scheme 40: Synthesis of Pd/Cu-BNP 139 and application of 139 in the synthesis of polycyclic triazoles 142.
Scheme 41: A probable mechanism for the synthesis of polycyclic triazoles 142.
Scheme 42: Synthesis of highly functionalized 1,2,3-triazole-fused 5-, 6-, and 7-membered rings 152–154.
Scheme 43: A probable mechanism for the synthesis of highly functionalized 1,2,3-triazole-fused 5-, 6-, and 7-...
Scheme 44: Synthesis of fully functionalized 1,2,3-triazolo-fused chromenes 162, 164, and 166 via the intramol...
Scheme 45: Ru-catalyzed synthesis of fully decorated triazoles 172.
Scheme 46: Synthesis of 4-cyano-1,2,3-triazoles 175.
Scheme 47: Synthesis of functionalized triazoles from the reaction of 1-alkyltriazenes 176 and azides 177 and ...
Scheme 48: Mechanism for the synthesis of functionalized triazoles from the reaction of 1-alkyltriazenes 176 a...
Beilstein J. Org. Chem. 2021, 17, 1096–1140, doi:10.3762/bjoc.17.86
Graphical Abstract
Scheme 1: General strategy for the enantioselective synthesis of N-containing heterocycles from N-tert-butane...
Scheme 2: Methodologies for condensation of aldehydes and ketones with tert-butanesulfinamides (1).
Scheme 3: Transition models for cis-aziridines and trans-aziridines.
Scheme 4: Mechanism for the reduction of N-tert-butanesulfinyl imines.
Scheme 5: Transition models for the addition of organomagnesium and organolithium compounds to N-tert-butanes...
Scheme 6: Synthesis of 2,2-dibromoaziridines 15 from aldimines 14 and bromoform, and proposed non-chelation-c...
Scheme 7: Diastereoselective synthesis of aziridines from tert-butanesulfinyl imines.
Scheme 8: Synthesis of vinylaziridines 22 from aldimines 14 and 1,3-dibromopropene 23, and proposed chelation...
Scheme 9: Synthesis of vinylaziridines 27 from aldimines 14 and α-bromoesters 26, and proposed transition sta...
Scheme 10: Synthesis of 2-chloroaziridines 28 from aldimines 14 and dichloromethane, and proposed transition s...
Scheme 11: Synthesis of cis-vinylaziridines 30 and 31 from aldimines 14 and bromomethylbutenolide 29.
Scheme 12: Synthesis of 2-chloro-2-aroylaziridines 36 and 32 from aldimines 14, arylnitriles 34, and silyldich...
Scheme 13: Synthesis of trifluoromethylaziridines 39 and proposed transition state of the aziridination.
Scheme 14: Synthesis of aziridines 42 and proposed state transition.
Scheme 15: Synthesis of 1-substituted 2-azaspiro[3.3]heptanes, 1-phenyl-2-azaspiro[3.4]octane and 1-phenyl-2-a...
Scheme 16: Synthesis of 1-substituted 2,6-diazaspiro[3.3]heptanes 48 from chiral imines 14 and 1-Boc-azetidine...
Scheme 17: Synthesis of β-lactams 52 from chiral imines 14 and dimethyl malonate (49).
Scheme 18: Synthesis of spiro-β-lactam 57 from chiral (RS)-N-tert-butanesulfinyl isatin ketimine 53 and ethyl ...
Scheme 19: Synthesis of β-lactam 60, a precursor of (−)-batzelladine D (61) and (−)-13-epi-batzelladine D (62)...
Scheme 20: Rhodium-catalyzed asymmetric synthesis of 3-substituted pyrrolidines 66 from chiral imine (RS)-63 a...
Scheme 21: Asymmetric synthesis of 1,3-disubstituted isoindolines 69 and 70 from chiral imine 67.
Scheme 22: Asymmetric synthesis of cis-2,5-disubstituted pyrrolidines 73 from chiral imine (RS)-71.
Scheme 23: Asymmetric synthesis of 3-hydroxy-5-substituted pyrrolidin-2-ones 77 from chiral imine (RS)-74.
Scheme 24: Asymmetric synthesis of 4-hydroxy-5-substituted pyrrolidin-2-ones 80 from chiral imines 79.
Scheme 25: Asymmetric synthesis of 3-pyrrolines 82 from chiral imines 14 and ethyl 4-bromocrotonate (81).
Scheme 26: Asymmetric synthesis of γ-amino esters 84, and tetramic acid derivative 86 from chiral imines (RS)-...
Scheme 27: Asymmetric synthesis of α-methylene-γ-butyrolactams 90 from chiral imines (Z,SS)-87 and ethyl 2-bro...
Scheme 28: Asymmetric synthesis of methylenepyrrolidines 92 from chiral imines (RS)-14 and 2-(trimethysilylmet...
Scheme 29: Synthesis of dibenzoazaspirodecanes from cyclic N-tert-butanesulfinyl imines.
Scheme 30: Stereoselective synthesis of cyclopenta[c]proline derivatives 103 from β,γ-unsaturated α-amino acid...
Scheme 31: Stereoselective synthesis of alkaloids (−)-angustureine (107) and (−)-cuspareine (108).
Scheme 32: Stereoselective synthesis of alkaloids (−)-pelletierine (112) and (+)-coniine (117).
Scheme 33: Synthesis of piperidine alkaloids (+)-dihydropinidine (122a), (+)-isosolenopsin (122b) and (+)-isos...
Scheme 34: Stereoselective synthesis of the alkaloids(+)-sedamine (125) from chiral imine (SS)-119.
Scheme 35: Stereoselective synthesis of trans-5-hydroxy-6-substituted-2-piperidinones 127 and 129 from chiral ...
Scheme 36: Stereoselective synthesis of trans-5-hydroxy-6-substituted ethanone-2-piperidinones 132 from chiral...
Scheme 37: Stereoselective synthesis of trans-3-benzyl-5-hydroxy-6-substituted-2-piperidinones 136 from chiral...
Scheme 38: Stereoselective synthesis of trans-5-hydroxy-6-substituted 2-piperidinones 139 from chiral imine 138...
Scheme 39: Stereoselective synthesis of ʟ-hydroxypipecolic acid 145 from chiral imine 144.
Scheme 40: Synthesis of 1-substituted isoquinolones 147, 149 and 151.
Scheme 41: Stereoselective synthesis of 3-substituted dihydrobenzo[de]isoquinolinones 154.
Scheme 42: Enantioselective synthesis of alkaloids (S)-1-benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (...
Scheme 43: Enantioselective synthesis of alkaloids (−)-cermizine B (171) and (+)-serratezomine E (172) develop...
Scheme 44: Stereoselective synthesis of (+)-isosolepnosin (177) and (+)-solepnosin (178) from homoallylamine d...
Scheme 45: Stereoselective synthesis of tetrahydroquinoline derivatives 184, 185 and 187 from chiral imines (RS...
Scheme 46: Stereoselective synthesis of pyridobenzofuran and pyridoindole derivatives 193 from homopropargylam...
Scheme 47: Stereoselective synthesis of 2-substituted 1,2,5,6-tetrahydropyridines 196 from chiral imines (RS)-...
Scheme 48: Stereoselective synthesis of 2-substituted trans-2,6-disubstituted piperidine 199 from chiral imine...
Scheme 49: Stereoselective synthesis of cis-2,6-disubstituted piperidines 200, and alkaloid (+)-241D, from chi...
Scheme 50: Stereoselective synthesis of 6-substituted piperidines-2,5-diones 206 and 1,7-diazaspiro[4.5]decane...
Scheme 51: Stereoselective synthesis of spirocyclic oxindoles 210 from chiral imines (RS)-53.
Scheme 52: Stereoselective synthesis of azaspiro compound 213 from chiral imine 211.
Scheme 53: Stereoselective synthesis of tetrahydroisoquinoline derivatives from chiral imines (RS)-214.
Scheme 54: Stereoselective synthesis of (−)-crispine A 223 from chiral imine (RS)-214.
Scheme 55: Synthesis of (−)-harmicine (228) using tert-butanesulfinamide through haloamide cyclization.
Scheme 56: Stereoselective synthesis of tetraponerines T1–T8.
Scheme 57: Stereoselective synthesis of phenanthroindolizidines 246a and (−)-tylophorine (246b), and phenanthr...
Scheme 58: Stereoselective synthesis of indoline, tetrahydroquinoline and tetrahydrobenzazepine derivatives 253...
Scheme 59: Stereoselective synthesis of (+)-epohelmin A (258) and (+)-epohelmin B (260) from aldimine (RS)-79.
Scheme 60: Stereoselective synthesis of (−)-epiquinamide (266) from chiral aldimine (SS)-261.
Scheme 61: Synthesis synthesis of (–)-hippodamine (273) and (+)-epi-hippodamine (272) using chiral sulfinyl am...
Scheme 62: Stereoselective synthesis of (+)-grandisine D (279) and (+)-amabiline (283).
Scheme 63: Stereoselective synthesis of (−)-epiquinamide (266) and (+)-swaisonine (291) from aldimine (SS)-126....
Scheme 64: Stereoselective synthesis of (+)-C(9a)-epi-epiquinamide (294).
Scheme 65: Stereoselective synthesis of (+)-lasubine II (298) from chiral aldimine (SS)-109.
Scheme 66: Stereoselective synthesis of (−)-epimyrtine (300a) and (−)-lasubine II (ent-302) from β-amino keton...
Scheme 67: Stereoselective synthesis of (−)-tabersonine (310), (−)-vincadifformine (311), and (−)-aspidospermi...
Scheme 68: Stereoselective synthesis of (+)-epohelmin A (258) and (+)-epohelmin B (260) from aldehyde 313 and ...
Scheme 69: Total synthesis of (+)-lysergic acid (323) from N-tert-butanesulfinamide (RS)-1.
Beilstein J. Org. Chem. 2021, 17, 977–982, doi:10.3762/bjoc.17.79
Graphical Abstract
Figure 1: Biologically relevant 2-oxydibenzofuran-containing structures 1–6.
Figure 2: Representative bioactive structures containing benzofuro-fused pyridine analogues 7–9.
Scheme 1: Strategy for metal-free access to benzofuropyridine 13.
Scheme 2: Electrophilic aromatic substitution of 6-hydroxybenzofuro[2,3-b]pyridine (13).
Scheme 3: Synthesis of isomeric oxazole-fused derivatives.
Scheme 4: Fused derivatives from 16.
Beilstein J. Org. Chem. 2021, 17, 891–907, doi:10.3762/bjoc.17.75
Graphical Abstract
Figure 1: Components of the LNPs. A) Lipid species and lipidated cell-penetrating peptides applied by postins...
Figure 2: LNPs with T7 pass through the transwell cell barrier and are taken up by target cells. HeLa (CCR5-n...
Figure 3: LNPs with Tat pass through the transwell cell barrier and are taken up by target cells. A) Percenta...
Figure 4: LNPs do not stimulate secretion of proinflammatory cytokines. A) GMCSF-primed MDMs were treated wit...
Figure 5: LNPs modestly affect cell viability in a cell-specific manner. HeLa (A) or HEK293T cells (B) were t...
Beilstein J. Org. Chem. 2021, 17, 819–865, doi:10.3762/bjoc.17.71
Graphical Abstract
Figure 1: Marketed drugs with acridine moiety.
Scheme 1: Synthesis of 4-arylacridinediones.
Scheme 2: Proposed mechanism for acridinedione synthesis.
Scheme 3: Synthesis of tetrahydrodibenzoacridinones.
Scheme 4: Synthesis of naphthoacridines.
Scheme 5: Plausible mechanism for naphthoacridines.
Figure 2: Benzoazepines based potent molecules.
Scheme 6: Synthesis of azepinone.
Scheme 7: Proposed mechanism for azepinone formation.
Scheme 8: Synthesis of benzoazulenen-1-one derivatives.
Scheme 9: Proposed mechanism for benzoazulene-1-one synthesis.
Figure 3: Indole-containing pharmacologically active molecules.
Scheme 10: Synthesis of functionalized indoles.
Scheme 11: Plausible mechanism for the synthesis of functionalized indoles.
Scheme 12: Synthesis of spirooxindoles.
Scheme 13: Synthesis of substituted spirooxindoles.
Scheme 14: Plausible mechanism for the synthesis of substituted spirooxindoles.
Scheme 15: Synthesis of pyrrolidinyl spirooxindoles.
Scheme 16: Proposed mechanism for pyrrolidinyl spirooxindoles.
Figure 4: Pyran-containing biologically active molecules.
Scheme 17: Synthesis of functionalized benzopyrans.
Scheme 18: Plausible mechanism for synthesis of benzopyran.
Scheme 19: Synthesis of indoline-spiro-fused pyran derivatives.
Scheme 20: Proposed mechanism for indoline-spiro-fused pyran.
Scheme 21: Synthesis of substituted naphthopyrans.
Figure 5: Marketed drugs with pyrrole ring.
Scheme 22: Synthesis of tetra-substituted pyrroles.
Scheme 23: Mechanism for silica-supported PPA-SiO2-catalyzed pyrrole synthesis.
Scheme 24: Synthesis of pyrrolo[1,10]-phenanthrolines.
Scheme 25: Proposed mechanism for pyrrolo[1,10]-phenanthrolines.
Figure 6: Marketed drugs and molecules containing pyrimidine and pyrimidinones skeletons.
Scheme 26: MWA-MCR pyrimidinone synthesis.
Scheme 27: Two proposed mechanisms for pyrimidinone synthesis.
Scheme 28: MWA multicomponent synthesis of dihydropyrimidinones.
Scheme 29: Proposed mechanism for dihydropyrimidinones.
Figure 7: Biologically active fused pyrimidines.
Scheme 30: MWA- MCR for the synthesis of pyrrolo[2,3-d]pyrimidines.
Scheme 31: Proposed mechanism for pyrrolo[2,3-d]pyrimidines.
Scheme 32: Synthesis of substituted pyrrolo[2,3-d]pyrimidine-2,4-diones.
Scheme 33: Probable pathway for pyrrolo[2,3-d]pyrimidine-2,4-diones.
Scheme 34: Synthesis of pyridopyrimidines.
Scheme 35: Plausible mechanism for the synthesis of pyridopyrimidines.
Scheme 36: Synthesis of dihydropyridopyrimidine and dihydropyrazolopyridine.
Scheme 37: Proposed mechanism for the formation of dihydropyridopyrimidine.
Scheme 38: Synthesis of thiopyrano[4,3-d]pyrimidines.
Scheme 39: Plausible mechanism for the synthesis of thiopyrano[4,3-d]pyrimidines.
Scheme 40: Synthesis of decorated imidazopyrimidines.
Scheme 41: Proposed mechanism for imidazopyrimidine synthesis.
Figure 8: Pharmacologically active molecules containing purine bases.
Scheme 42: Synthesis of aza-adenines.
Scheme 43: Synthesis of 5-aza-7-deazapurines.
Scheme 44: Proposed mechanism for deazapurines synthesis.
Figure 9: Biologically active molecules containing pyridine moiety.
Scheme 45: Synthesis of steroidal pyridines.
Scheme 46: Proposed mechanism for steroidal pyridine.
Scheme 47: Synthesis of N-alkylated 2-pyridones.
Scheme 48: Two possible mechanisms for pyridone synthesis.
Scheme 49: Synthesis of pyridone derivatives.
Scheme 50: Postulated mechanism for synthesis of pyridone.
Figure 10: Biologically active fused pyridines.
Scheme 51: Benzimidazole-imidazo[1,2-a]pyridines synthesis.
Scheme 52: Mechanism for the synthesis of benzimidazole-imidazo[1,2-a]pyridines.
Scheme 53: Synthesis of pyrazolo[3,4-b]pyridine-5-spirocycloalkanedione derivatives.
Scheme 54: Proposed mechanism for spiro-pyridines.
Scheme 55: Functionalized macrocyclane-fused pyrazolo[3,4-b]pyridine derivatives.
Scheme 56: Mechanism postulated for macrocyclane-fused pyrazolo[3,4-b]pyridine.
Scheme 57: Generation of pyrazolo[3,4-b]pyridines.
Scheme 58: Proposed mechanism for the synthesis of pyrazolo[3,4-b]pyridines.
Scheme 59: Proposed mechanism for the synthesis of azepinoindole.
Figure 11: Pharmaceutically important molecules with quinoline moiety.
Scheme 60: Povarov-mediated quinoline synthesis.
Scheme 61: Proposed mechanism for Povarov reaction.
Scheme 62: Synthesis of pyrazoloquinoline.
Scheme 63: Plausible mechanism for pyrazoloquinoline synthesis.
Figure 12: Quinazolinones as pharmacologically significant scaffolds.
Scheme 64: Four-component reaction for dihydroquinazolinone.
Scheme 65: Proposed mechanism for dihydroquinazolinones.
Scheme 66: Synthesis purine quinazolinone and PI3K-δ inhibitor.
Scheme 67: Synthesis of fused benzothiazolo/benzoimidazoloquinazolinones.
Scheme 68: Proposed mechanism for fused benzothiazolo/benzoimidazoloquinazolinones.
Scheme 69: On-water reaction for synthesis of thiazoloquinazolinone.
Scheme 70: Proposed mechanism for the thiazoloquinazolinone synthesis.
Scheme 71: β-Cyclodextrin-mediated synthesis of indoloquinazolinediones.
Scheme 72: Proposed mechanism for synthesis of indoloquinazolinediones.
Figure 13: Triazoles-containing marketted drugs and pharmacologically active molecules.
Scheme 73: Cu(I) DAPTA-catalyzed 1,2,3-triazole formation.
Scheme 74: Mechanism for Cu(I) DAPTA-catalyzed triazole formation.
Scheme 75: Synthesis of β-hydroxy-1,2,3-triazole.
Scheme 76: Proposed mechanism for synthesis of β-hydroxy-1,2,3-triazoles.
Scheme 77: Synthesis of bis-1,2,4-triazoles.
Scheme 78: Proposed mechanism for bis-1,2,4-triazoles synthesis.
Figure 14: Thiazole containing drugs.
Scheme 79: Synthesis of a substituted thiazole ring.
Scheme 80: Synthesis of pyrazolothiazoles.
Figure 15: Chromene containing drugs.
Scheme 81: Magnetic nanocatalyst-mediated aminochromene synthesis.
Scheme 82: Proposed mechanism for the synthesis of chromenes.
Beilstein J. Org. Chem. 2021, 17, 558–568, doi:10.3762/bjoc.17.50
Graphical Abstract
Figure 1: Structure of biologically active phthalazine derivatives.
Scheme 1: Synthetic route to aminophthalazinones 5 and 6.
Figure 2: Proposed catalytic cycles for the amination of 4-bromophthalazinones of type 3 (Phthal: phthalazino...
Scheme 2: Synthesis of 4-amino- and 4-polyaminophthalazinones 5 and 6 (the yields refer to the isolated compo...
Figure 3: The phthalazinone derivatives that were used to test the complexation of Cu(II) ions.
Scheme 3: The proposal of the fragmentation pathway of the Cu(II) complex with compound 7.
Figure 4: Structure of complex 17.
Figure 5: Molecular structure of complex 17 with atom numbering scheme. The anisotropic displacement paramete...
Figure 6: Determination of relative cell viability (% of control) in different cell lines (HT-29; PC-3 and L-...
Figure 7: Cytotoxic properties of the phthalazinone derivatives expressed as IC50 after 72 h of cell treatmen...
Beilstein J. Org. Chem. 2021, 17, 511–518, doi:10.3762/bjoc.17.45
Graphical Abstract
Scheme 1: a) Schematic representation of a perfluorohexane-stabilized microbubble with a fluorinated lipopept...
Scheme 2: Solid-phase synthesis of F-lipopeptides 1–3 and hydrocarbon counterpart 4.
Figure 1: Adsorption kinetics of perfluoroalkylated lipopeptides 1–3 and the hydrocarbon analog 4 at the air/...
Figure 2: Adsorption of perfluoroalkylated lipopeptides 1–3 and hydrocarbon analog 4 on DPPC monolayers sprea...
Figure 3: Optical micrographs and corresponding size distribution of the perfluorohexane-stabilized microbubb...
Figure 4: Half-lives of microbubbles (25 °C) containing F-lipopeptides 1–3 and hydrocarbon analog 4.
Beilstein J. Org. Chem. 2021, 17, 461–484, doi:10.3762/bjoc.17.41
Graphical Abstract
Figure 1: Phosphonopeptides, phosphonodepsipeptides, peptides, and depsipeptides.
Figure 2: The diverse strategies for phosphonodepsipeptide synthesis.
Scheme 1: Synthesis of α-phosphonodepsidipeptides as inhibitors of leucine aminopeptidase.
Figure 3: Structure of 2-hydroxy-2-oxo-3-[(phenoxyacetyl)amino]-1,2-oxaphosphorinane-6-carboxylic acid (16).
Scheme 2: Synthesis of α-phosphonodepsidipeptide 17 as coupling partner for cyclen-containing phosphonodepsip...
Scheme 3: Synthesis of α-phosphonodepsidipeptides containing enantiopure hydroxy ester as VanX inhibitors.
Scheme 4: Synthesis of α-phosphonodepsidipeptides as VanX inhibitors.
Scheme 5: Synthesis of optically active α-phosphonodepsidipeptides as VanX inhibitors.
Scheme 6: The synthesis of phosphonodepsipeptides through a thionyl chloride-catalyzed esterification of N-Cb...
Scheme 7: Synthesis of α-phosphinodipeptidamide as a hapten.
Scheme 8: Synthesis of α-phosphonodepsioctapeptide 41.
Scheme 9: Synthesis of phosphonodepsipeptides via an in situ-generated phosphonochloridate.
Scheme 10: Synthesis of α-phosphonodepsitetrapeptides 58 as inhibitors of the aspartic peptidase pepsin.
Scheme 11: Synthesis of a β-phosphonodepsidipeptide library 64.
Scheme 12: Synthesis of another β-phosphonodepsidipeptide library.
Scheme 13: Synthesis of γ-phosphonodepsidipeptides.
Scheme 14: Synthesis of phosphonodepsipeptides 85 as folylpolyglutamate synthetase inhibitors.
Scheme 15: Synthesis of the γ-phosphonodepsitripeptide 95 as an inhibitor of γ-gutamyl transpeptidase.
Scheme 16: Synthesis of phosphonodepsipeptides as inhibitors and probes of γ-glutamyl transpeptidase.
Scheme 17: Synthesis of phosphonyl depsipeptides 108 via DCC-mediated condensation and oxidation.
Scheme 18: Synthesis of phosphonodepsipeptides 111 with BOP and PyBOP as coupling reagents.
Scheme 19: Synthesis of optically active phosphonodepsipeptides with BOP and PyBOP as coupling reagents.
Scheme 20: Synthesis of phosphonodepsipeptides with BroP and TPyCIU as coupling reagents.
Scheme 21: Synthesis of a phosphonodepsipeptide hapten with BOP as coupling reagent.
Scheme 22: Synthesis of phosphonodepsitripeptide with BOP as coupling reagent.
Scheme 23: Synthesis of norleucine-derived phosphonodepsipeptides 135 and 138.
Scheme 24: Synthesis of norleucine-derived phosphonodepsipeptides 141 and 144.
Scheme 25: Solid-phase synthesis of phosphonodepsipeptides.
Scheme 26: Synthesis of phosphonodepsidipeptides via the Mitsunobu reaction.
Scheme 27: Synthesis of γ-phosphonodepsipeptide via the Mitsunobu reaction.
Scheme 28: Synthesis of phosphonodepsipeptides via a multicomponent condensation reaction.
Scheme 29: Synthesis of phosphonodepsipeptides with a functionalized side-chain via a multicomponent condensat...
Scheme 30: High yielding synthesis of phosphonodepsipeptides via a multicomponent condensation.
Scheme 31: Synthesis of optically active phosphonodepsipeptides via a multicomponent condensation reaction.
Scheme 32: Synthesis of N-phosphoryl phosphonodepsipeptides.
Scheme 33: Synthesis of phosphonodepsipeptides via the alkylation of phosphonic monoesters.
Scheme 34: Synthesis of phosphonodepsipeptides as inhibitors of aspartic protease penicillopepsin.
Scheme 35: Synthesis of phosphonodepsipeptides as prodrugs.
Scheme 36: Synthesis of phosphonodepsithioxopeptides 198.
Scheme 37: Synthesis of phosphonodepsipeptides.
Scheme 38: Synthesis of phosphonodepsipeptides with C-1-hydroxyalkylphosphonic acid.
Scheme 39: Synthesis of phosphonodepsipeptides with C-1-hydroxyalkylphosphonate via the rhodium-catalyzed carb...
Scheme 40: Synthesis of phosphonodepsipeptides with a C-1-hydroxyalkylphosphonate motif via a copper-catalyzed...
Beilstein J. Org. Chem. 2021, 17, 431–438, doi:10.3762/bjoc.17.39
Graphical Abstract
Scheme 1: Chemistry of the CF3 anion generated from HCF3. a) Decomposition of the trifluoromethyl anion to di...
Figure 1: Trifluoromethyl ketones. a) Hydrolysis of trifluoromethyl ketones. b) Selected examples of biologic...
Scheme 2: Trifluoromethylation of esters by HCF3 by a) Russell and Roques (1998), b) Prakash and co-workers (...
Scheme 3: Substrate scope of esters 1 for trifluoromethylation by HCF3 under the optimized conditions. aDeter...
Beilstein J. Org. Chem. 2021, 17, 97–104, doi:10.3762/bjoc.17.10
Graphical Abstract
Scheme 1: The synthesis of the C3-symmetrical tetraethylene glycol-decorated peptide amphiphile I and the azi...
Scheme 2: Synthesis of the sulfated peptide amphiphile II by copper-catalyzed azide–alkyne cyclization.
Figure 1: Analysis of the self-assembly behavior of I by A: CD-spectra of 5, 10, 25 or 50 µM aqueous solution...
Figure 2: Analysis of the supramolecular polymerization of II by A: CD-spectra of a 25 µM solution in TRIS bu...
Figure 3: Concentration-dependent relative L-selectin binding of the supramolecular polymers I and II in HEPE...
Beilstein J. Org. Chem. 2021, 17, 28–41, doi:10.3762/bjoc.17.4
Graphical Abstract
Figure 1: Homotropane (azabicyclononane) systems.
Figure 2: Alkaloids (−)-adaline (1), (+)-euphococcinine (2) and (+)-N-methyleuphococcinine (3).
Scheme 1: Synthetic strategies before 1995.
Scheme 2: Synthesis (±)-adaline (1) and (±)-euphococcinine (2). Reagents and conditions: i) 1. dihydropyran, ...
Scheme 3: Synthesis (+)-euphococcinine (2). Reagents and conditions: i) H2O2, SeO2 (cat), acetone, rt, 88%; i...
Scheme 4: Synthesis (+)-euphococcinine (2). Reagents and conditions: i) 2,4-bis(4-phenoxyphenyl)-1,3-dithia-2...
Scheme 5: Synthesis of (±)-euphococcinine precursor (±)-42. Reagents and conditions: i) Bu3SnH, AIBN, toluene...
Scheme 6: Synthesis of (−)-adaline (1). Reagents and conditions: i) LiH2NBH3, THF, 40 °C, 88%; ii) TPAP, NMO,...
Scheme 7: Synthesis of (−)-adaline (1) and (−)-euphococcinine (2). Reagents and conditions: i) 1. BuLi, t-BuO...
Scheme 8: Synthesis of (−)-adaline (1). Reagents and conditions: i) Ref. [52]; ii) Et3N, TBDMSOTf, CH2Cl2, 0 °C t...
Scheme 9: Synthesis of (+)-euphococcinine (2). Reagents and conditions: i) 1. Cp2ZrCl2,AlMe3, CH2Cl2; 2. p-me...
Scheme 10: Synthesis of (−)-adaline 1. Reagents and conditions: i) 1. CuBr.DMS, Et2O/DMS, -42 ºC; 2. 1-heptyne...
Scheme 11: Synthesis of (−)-euphococcinine (2) and (−)-adaline (1). Reagents and conditions: i) 102, KHMDS, Et2...
Scheme 12: Synthesis of N-methyleuphococcinine 3. Reagents and conditions: i) 108 (1.5 equiv), 3,5-di-F-C6H3B(...
Beilstein J. Org. Chem. 2020, 16, 3104–3108, doi:10.3762/bjoc.16.260
Graphical Abstract
Scheme 1: The construction of tetrafluorinated piperidines from nitrones.
Scheme 2: The scope of the annelation reaction for the synthesis of piperidines. Isolated yields are shown. a...
Scheme 3: The proposed mechanism of the photoredox annelation reaction (asc = ascorbic acid).
Beilstein J. Org. Chem. 2020, 16, 3059–3068, doi:10.3762/bjoc.16.255
Graphical Abstract
Figure 1: Tandem acetate rearrangement/Nazarov cyclization of different substrates.
Figure 2: DFT-computed energy profile of the tandem Au(I)-catalyzed [3,3]-rearrangement/Nazarov reaction of 3...
Figure 3: DFT-computed energy profile of the tandem Au(I)-catalyzed [3,3]-rearrangement/Nazarov reaction of 2...
Figure 4: Computed comparison of the NBO charges of 2- and 3-substituted substrates.
Figure 5: Single-step transformation of IV to IX.
Figure 6: Triflate-promoted hydrogen abstraction and protodeauration with HOTf.
Figure 7: Triflate-mediated abstraction of the hydrogen atom Ha and protodeauration.
Scheme 1: Synthesis of the enynyl acetate starting material 14.
Scheme 2: Synthesis and cyclization of enynyl acetate 20.
Beilstein J. Org. Chem. 2020, 16, 2831–2853, doi:10.3762/bjoc.16.233
Graphical Abstract
Figure 1: Some selected self-sorting outcomes and their qualitative and quantitative assessment.
Figure 2: Illustration of an integrative vs a non-integrative self-sorting.
Figure 3: The pH-driven four-component 2-fold completive self-sorting based on host–guest chemistry.
Figure 4: (a) The monomers 5 and 6 and their H-bonding array. (b) The hydrogen-bonded octameric and tetrameri...
Figure 5: (a) Two new Zn4L6-type cages. (b) The encapsulation of C70 induced distinct reconstitutions within ...
Figure 6: The formation of octahedral cages (a) [Co6(10')4]12+ and (b) [Co6(11')4]12+. (c) The 2-fold complet...
Figure 7: Exchange of Ag+ for Au+ ions in poly-NHC ligand-based organometallic assemblies.
Figure 8: The reversible interconversion between the three-component rectangle [Cu4(16)2(17)2]4+ and the four...
Figure 9: a) Chemical structure of the monomer 20 with its quadruple hydrogen-bonding array and a metal-affin...
Figure 10: Communication between the nanoswitch 21 and the supramolecular assemblies [Cu4(22)2(24)2]4+ or [Cu6(...
Figure 11: (a) The chemical structures and cartoon representations of the switch 25, the decks 26 and 27, and ...
Figure 12: Double self-sorting leads to a catalytic machinery in SelfSORT-II, in which the 46 kHz-nanorotor ac...
Figure 13: ON/OFF control of a networked catalytic catch–release system.
Figure 14: A multicomponent information system for the reversible reconfiguration of switchable dual catalysis....
Figure 15: a) The chemically fueled cascaded ion translocation, monitored by distinct emission colors. b) Work...
Figure 16: Cyclic metallosupramolecular transformations.
Figure 17: Fully reversible multiple-state rearrangement of metallosupramolecular architectures depending upon...
Figure 18: The selective encapsulation and sequential release of guests in a self-sorted mixture of three tetr...
Figure 19: Two catalytic reactions are alternately controlled by a toggle nanoswitch.
Figure 20: A biped walking along a tetrahedral track and unfolding its catalytic action. Adapted with permissi...
Figure 21: A three state supramolecular AND logic gate.
Figure 22: Four-component nanorotor and its catalytic activity. Adapted with permission from (Biswas, P. K.; S...
Beilstein J. Org. Chem. 2020, 16, 2709–2718, doi:10.3762/bjoc.16.221
Graphical Abstract
Figure 1: A) The molecular structures of the branched peptides Nap-ffk(NH2-DEDDDLLIG)y (1) and Nap-ffk(AcNH-D...
Scheme 1: Synthetic route to the branched peptides. (i) HBTU, DIPEA, DMF, 12 h, rt, (ii) TFA, 2 h, rt, and (i...
Figure 2: A) LC–MS spectrum of the proteolytic products after 1 (5 mM) was incubated with proteinase K (5 U/m...
Figure 3: Optical images of solutions of 1 and 2 (5 mM), respectively, with or without proteinase K (5 U/mL) ...
Figure 4: TEM images of the branched peptides before and after the addition of proteinase K into the solution...
Figure 5: Cell viability of HeLa and Saos-2 cells treated with 1 (A) and 2 (B).
Figure 6: Confocal images of HeLa cells treated with a mixture of RPE (8 μg/mL) and A) 1 (400 μM) or B) 2 (40...
Beilstein J. Org. Chem. 2020, 16, 2663–2670, doi:10.3762/bjoc.16.216
Graphical Abstract
Figure 1: The natural product piperine (1) is the inspiration for this work; the crystal structure is shown [14]....
Scheme 1: The attempted synthesis of 6 (a diastereoisomer of 2) via a one-step 1,2-difluorination reaction [24]. ...
Scheme 2: The attempted synthesis of 2 via a stepwise fluorination approach (ether series). THF = tetrahydrof...
Scheme 3: Synthesis of compound 2 via a stepwise fluorination approach (ester series). DIC = diisopropylcarbo...
Figure 2: Conformational analysis of 2 by DFT and NMR. The numbering scheme for NMR spins is given on structu...
Figure 3: Analog 2 has greater stability to UV light than does piperine (1).
Figure 4: Biological activity of piperine (1) and derivative 2. (a) Inihbition of AChE by 1 (IC50 >1000 μM) a...
Beilstein J. Org. Chem. 2020, 16, 2589–2597, doi:10.3762/bjoc.16.210
Graphical Abstract
Figure 1: “Record player” approach for molecular spin switching. a) General principle b) Variation of the sub...
Scheme 1: Synthesis of the nitroso compounds 3 and 6 using the two different methods described by Wegner et a...
Scheme 2: Synthesis of azopyridines 11, 14, 16 and 18 by nucleophilic aromatic substitution.
Scheme 3: Synthesis of 3-(3-bromophenylazo)-4-cyanopyridine (20), which was hydrolyzed to yield 3-(3-bromophe...
Scheme 4: Modular approach for the C–C connection of the Ni(II)-porphyrin 22 and the different 4-substituted ...
Scheme 5: Cleavage of 1f to yield disulfide 1g [34].
Figure 2: Hammett plot of the investigated pyridine substituents [36].
Figure 3: UV–vis spectra of 1e (top), 1h (left) and 1j (right) in acetone water (1:9) (solid line) and after ...
Beilstein J. Org. Chem. 2020, 16, 2201–2211, doi:10.3762/bjoc.16.185
Graphical Abstract
Scheme 1: DNA-targeting roles of the structural components incorporated in the design of the novel small mole...
Scheme 2: Synthesis of compound 4. Conditions: a) mono-N-Boc-ethylenediamine, DMF, 90 °C; b) i) trifluoroacet...
Figure 1: UV–vis titrations of compound 4 (c = 1.0 × 10−6 M), with ct-DNA at pH 7.0 (a) and at pH 5 (b). Inse...
Figure 2: a) CD titration of ct-DNA (c = 3.0 × 10−5 M) with compound 4 at pH 7.0 (Na cacodylate buffer, I = 0...
Figure 3: CD titration of poly(rA)–poly(rU) (c = 3.0 × 10−5 M) with compound 4 at a) pH 7.0 (Na cacodylate bu...
Figure 4: CD titration of ds-DNAs (c = 3.0 × 10−5 M) with 4 for ratio r[4]/ [DNA] = 0.4. Done at pH 5.0 (Na c...
Figure 5: ITC experiments of poly(dAdT)–poly(dAdT) (c = 5.0 × 10−5 M) titrated with compound 4. Dots represen...
Figure 6: AFM image of a) ct-DNA showing a fibre-like structure with a length of several micrometres; b) upon...
Beilstein J. Org. Chem. 2020, 16, 2119–2126, doi:10.3762/bjoc.16.179
Graphical Abstract
Figure 1: Basicity and nucleophilicity switching of the 4-(N,N-dimethylamino)pyridine “record player” molecul...
Scheme 1: Synthesis of 4-N,N-dimethylamino record player molecule 1 by Suzuki reaction between Ni-porphyrin p...
Figure 2: Composition of the different states of porphyrin 1 (1 mM) in the PSS at 530 nm and 435 nm, determin...
Figure 3: a) UV–vis cuvette with a solution of porphyrin 1 (13.1 µM in THF) and the corresponding UV–vis spec...
Scheme 2: General scheme of the nitroaldol (Henry) reaction that was used to investigate photoswitchable cata...
Scheme 3: DMAP (2), azopyridine trans-4, record player trans- and cis-1 and Ni-porphyrin 8 were used in kinet...
Figure 4: Conversion of 4-nitrobenzaldehyde (6) in the Henry reaction with nitroethane (5) as a function of t...
Beilstein J. Org. Chem. 2020, 16, 2073–2079, doi:10.3762/bjoc.16.174
Graphical Abstract
Figure 1: Pharmacologically active nonracemic phosphonates with heterocyclic moieties.
Figure 2: Starting nonracemic 4-nitro-2-oxophosphonates.
Scheme 1: Intermolecular N-methylation of reduction product 7.
Scheme 2: Synthesis of pyrrolidinyl phosphonic acids 11a–d.
Figure 3: ORTEP diagram of (2R,3R,4S)-10a.
Scheme 3: Synthesis of tetrahydropyranylphosphonates 13a–f via diastereoselective Henry/acetalyzation reactio...
Figure 4: ORTEP diagram of (2S,3R,4S,5S,6R)-13b.
Scheme 4: Synthesis of (3,4-dihydro-2H-pyran-5-yl)phosphonate 14.